YMAB - Y-Mabs Therapeutics Inc
IEX Last Trade
14.31
0.290 2.027%
Share volume: 240,613
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$14.02
0.29
2.07%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-07 | 2023-03-30 | 2023-05-08 | 2023-08-10 | 2023-11-13 | 2024-02-29 | 2024-05-07 | |
| Total revenue | 10.797 M | 12.537 M | 31.447 M | 20.251 M | 20.751 M | 20.454 M | 23.363 M | 19.931 M | |
| Cost of revenue | 1.140 M | 2.475 M | 2.021 M | 2.083 M | 4.649 M | 2.595 M | 2.039 M | 2.097 M | |
| Gross profit | 9.657 M | 10.062 M | 29.426 M | 18.168 M | 16.102 M | 17.859 M | 21.324 M | 17.834 M | |
| 4.19% | 192.45% | -38.26% | -11.37% | 10.91% | 19.40% | -16.37% | |||
| Operating expenses | 49.502 M | 36.079 M | 30.580 M | 25.669 M | 23.325 M | 25.558 M | 24.523 M | 24.692 M | |
| Selling general and admin | 23.082 M | 13.626 M | 10.793 M | 12.251 M | 11.270 M | 10.200 M | 11.135 M | 11.425 M | |
| Research and development | 26.420 M | 22.453 M | 19.787 M | 13.418 M | 12.055 M | 15.358 M | 13.388 M | 13.267 M | |
| Total expenses | 50.742 M | 38.554 M | 32.601 M | 27.752 M | 27.974 M | 28.203 M | 26.562 M | 26.839 M | |
| -24.02% | -15.44% | -14.87% | 0.80% | 0.82% | -5.82% | 1.04% | |||
| Operating income | -39.945 M | -26.017 M | -1.154 M | -7.501 M | -7.223 M | -7.749 M | -3.199 M | -6.908 M | |
| Ebit | -39.945 M | -26.017 M | -1.154 M | -7.501 M | -7.223 M | -7.749 M | -3.199 M | -6.908 M | |
| Pretax income | -41.131 M | -27.526 M | 1.157 M | -6.390 M | -6.123 M | -7.560 M | -793.000 K | -6.469 M | |
| -33.08% | -104.20% | -652.29% | -4.18% | 23.47% | -89.51% | 715.76% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 179.000 K | 187.000 K | 195.000 K | 160.000 K | |
| Net income basic | -41.131 M | -27.526 M | 1.157 M | -6.390 M | -6.302 M | -7.747 M | -988.000 K | -6.629 M | |
| 33.08% | 104.20% | -652.29% | 1.38% | -22.93% | 87.25% | -570.95% | |||
| Net income | -41.131 M | -27.526 M | 1.157 M | -6.390 M | -6.302 M | -7.747 M | -988.000 K | -6.629 M | |
| 33.08% | 104.20% | -652.29% | 1.38% | -22.93% | 87.25% | -570.95% |